Articles Vol. 63 No. 6 (2022) 09/11/2022

EFFECTS OF CYCLOPHOSPHAMIDE ON BLADDER AND RENAL FUNCTION IN PATIENTS WITH BREAST CANCER

Bui Dang Minh Tri1,2, Bui Dang Phuong Chi3,4, Doan Thanh Truc3,4, Tran Minh Sang5,6
1 Pham Ngoc Thach University of Medicine
2 Trường Đại học Y khoa Phạm Ngọc Thạch
3 Tay Do University
4 Trường Đại học Tây Đô
5 Thu Duc Hospital
6 Bệnh viện thành phố Thủ Đức
Corresponding author: drtribui1@gmail.com
DOI: 10.52163/yhc.v63i6.452
11 Views
0 Downloads
Keywords
Cyclophosphamide, bladder and renal function, breast cancer.
Abstract

Objective: To investigate the effect of Cyclophosphomid on bladder and renal function in breast
cancer patients.
Subjects and methods: Descriptive-prospective cohort study, longitudinal follow-up on 68
breast cancer patients at Thu Duc City Hospital who were treated with a regimen containing
Cyclophosphamide for 4-6 cycles.
Results: Common clinical adverse effects of Cyclophosphamide on renal and bladder function
were hypogastric pain (13.24%), hematuria (16.17%). Less common manifestations were urinary
frequency (10.29%), painful urination (8.82%), cloudy urine (5.88%) and dysuria (4.41%). In the
urine before and after treatment with Cyclophosphamide, there was a change in Microalbumin
(from 5.24±0.64 to 16.21±2.01mg/dl). The results of cystoscopy showed that 19.05% of patients
had lesions. In which, 14.29% of bladder mucosal inflammation, 4.76% had ulceration and necrosis,
there was not a bladder atrophy case. The rate of patients with bladder toxicity was 13.2%, the rate
of patients without bladder toxicity was 86.8%.
Conclusion: Common clinical side effects of Cyclophosphamide on renal and bladder function
were hypogastric pain, hematuria. In the urine before and after treatment with Cyclophosphamide
there was a change in Microalbumin. Cystoscopy showed 14.29% of bladder mucosal inflammation,
4.76% had ulceration and necrosis. The proportion of patients with bladder toxicity was 13.2%.

References
[1]
Siegel R, Naishadham D, Jemal A, Cancer Google Scholar
[2]
statistics, 2013. CA Cancer J Clin, 63(1): 11-30, Google Scholar
[3]
Cserni G, The new TNM-based staging of breast Google Scholar
[4]
cancer. Virchows Arch, 472(5): 697-703, 2018. Google Scholar
[5]
Ferlay J, Cancer incidence and mortality Google Scholar
[6]
worldwide: sources, methods and major patterns Google Scholar
[7]
in GLOBOCAN 2012. International journal of Google Scholar
[8]
cancer, 136(5): E359-E386, 2015. Google Scholar
[9]
Khokher S, Clinicopathologic profile of breast Google Scholar
[10]
cancer patients in Pakistan: ten years data of a Google Scholar
[11]
local cancer hospital. Asian Pacific Journal of Google Scholar
[12]
Cancer Prevention, 13(2): 693-698, 2012. Google Scholar
[13]
Moore MA, Cancer epidemiology in mainland Google Scholar
[14]
South-East Asia-past, present and future. Asian Google Scholar
[15]
Pac J Cancer Prev, 11(Suppl 2): 67-80, 2010. Google Scholar
[16]
Han SJ, Prognostic significance of interactions Google Scholar
[17]
between ER alpha and ER beta and lymph node Google Scholar
[18]
status in breast cancer cases. Asian Pac J Cancer Google Scholar
[19]
Prev, 14(10): 6081-4, 2013. Google Scholar
[20]
George P, Haemorrhagic cystitis and Google Scholar
[21]
cyclophosphamide. Lancet, 2(7314): 942, 1963. Google Scholar
[22]
Plotz PH, Bladder complications in patients Google Scholar
[23]
receiving cyclophosphamide for systemic lupus Google Scholar
[24]
erythematosus or rheumatoid arthritis. Ann Intern Google Scholar
[25]
Med, 91(2): 221-3, 1979. Google Scholar
[26]
Varma PP, Subba DB, Madhoosudanan P, Google Scholar
[27]
Cyclophosphamide induced haemorrhagic cystitis Google Scholar
[28]
(a case report). Med J Armed Forces India, 54(1): Google Scholar
[29]
-60, 1998. Google Scholar
[30]
Kaldor JM, Day NE, Kittelmann B et al., Google Scholar
[31]
Bladder tumours following chemotherapy and Google Scholar
[32]
radiotherapy for ovarian cancer: a case-control Google Scholar
[33]
study. Int J Cancer, 63(1): 1-6, 1995. Google Scholar